Amendment to Schedule 13D Filing for Apimeds Pharmaceuticals US, Inc.

This filing is an amendment to a Schedule 13D for Apimeds Pharmaceuticals US, Inc. (APUS), filed by Inscobee Inc. and Apimeds Inc. The amendment addresses a dispute regarding a written consent executed on March 20, 2026, by majority stockholders to remove and appoint directors, and to change executive officers. MindWave Innovations Inc. issued a press release challenging these actions, alleging a breach of a Support and Lock-Up Agreement. The filing asserts that the actions taken via written consent are valid and do not violate the agreement, as they fall outside the scope of any granted proxy. It also highlights that director removal is permissible under Delaware General Corporate Law. The Reporting Persons reserve all rights and intend to defend the validity of the written consent against any potential litigation from former officers and directors.